Mobonib

Mobonib uses and dosage

Mobonib (Mobocertinib), Exkivity is a prescription medicine used to treat lung cancer. Mobocertinib is an unmet breakthrough for NSCLC with EGFR ex20ins+. Mobocertinib is the first and only approved effective drug for EGFR ex20ins+. In china, lung cancer is the most Frequently diagnosed cancer, and NSCLC accounts for 80% of all lung cancer cases. Of those patients diagnosed with EGFR-mutated NSCLC, up to 10% have harbor exon20 insertions. Mobocertinib works by slowing or stopping the growth of cancer cells. Mobonib is manufactured by Ziska Pharma Ltd. in Bangladesh. Mobocertinib has to take 160mg (4 capsules) orally once a day.

Mobonib side effects

The most common adverse reactions of Mobocertinib are: Diarrhea, nausea, vomiting, loss of appetite, stomach/abdominal pain, heartburn, mouth sores, weight loss, dry skin, and runny nose.

Originator brand

EXKIVITY by TAKEDA PHARMS USA

Made by

Ziska Pharma

This information is provided for reference only and is not medical advice. Always consult a qualified healthcare professional.